Nortriptyline
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00540 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 21 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | attention deficit-hyperactivity disorder | KG + DL |
| 2 | attention deficit hyperactivity disorder, inattentive type | KG + DL |
| 3 | faciodigitogenital syndrome | KG + DL |
| 4 | chondromyxoid fibroma | KG + DL |
| 5 | specific developmental disorder | KG + DL |
| 6 | benign paroxysmal torticollis of infancy | KG + DL |
| 7 | agoraphobia | KG + DL |
| 8 | trichotillomania | KG + DL |
| 9 | Tourette syndrome | KG + DL |
| 10 | major affective disorder | KG + DL |
| 11 | obsessive-compulsive disorder | KG + DL |
| 12 | obesity disorder | KG + DL |
| 13 | schizophrenia | KG + DL |
| 14 | migraine with brainstem aura | KG + DL |
| 15 | migraine disorder | KG + DL |
| 16 | hypervitaminosis | KG + DL |
| 17 | histrionic personality disorder (disease) | KG + DL |
| 18 | paranoid personality disorder | KG + DL |
| 19 | schizoid personality disorder | KG + DL |
| 20 | schizotypal personality disorder | KG + DL |
| 21 | proximal 16p11.2 microdeletion syndrome | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.